Reports Q4 revenue $12.75M, consensus $14.09M. “We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over 90% to $38.8 million,” said Denny Lanfear, Coherus chairman and CEO. “We are now strategically positioned with growing revenues from our foundational PD-1 inhibitor, potential deal opportunities across the portfolio and geographies, and two promising pipeline candidates with multiple 2026 clinical readouts.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Options Volatility and Implied Earnings Moves Today, March 09, 2026
- CHRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Coherus Biosciences Completes $47 Million Equity Offering
- Coherus Oncology 28.6M share Spot Secondary priced at $1.75
- Coherus Oncology announces common stock offering, no amount given